Bausch Health Cos (NYSE:BHC) Sees Strong Trading Volume – What’s Next?

Bausch Health Cos Inc. (NYSE:BHC) saw unusually-high trading volume on Thursday . Approximately 1,530,022 shares traded hands during trading, a decline of 22% from the previous session’s volume of 1,954,552 shares.The stock last traded at $5.9330 and had previously closed at $5.59.

Bausch Health Cos News Summary

Here are the key news stories impacting Bausch Health Cos this week:

• Positive Sentiment: Reported strength in revenue and adjusted profitability — BHC delivered reported Q1 revenue of $2.52B (up ~12% yoy) with adjusted EBITDA of $837M (up 27% yoy) and adjusted EPS of $0.78, signaling improving underlying business momentum. PR Newswire Release
• Positive Sentiment: Growth driven by key franchises — Management cited strength at Salix and Solta and twelve consecutive quarters of year‑over‑year revenue and adjusted EBITDA growth for Bausch Health ex-Bausch + Lomb, supporting a positive operational outlook. Yahoo: Q1 Highlights
• Positive Sentiment: Reaffirmed full‑year guidance and cash flow — The company reaffirmed FY 2026 targets for revenue, adjusted EBITDA and adjusted operating cash flow and reported $319M of adjusted cash flow from operations in Q1, reducing near‑term execution risk. PR Newswire Release
• Neutral Sentiment: Investor readouts and call details available — The earnings call transcript and analyst summaries provide more color on product mix, cost dynamics and timing assumptions for the outlook; useful for investors digging beyond headline numbers. Seeking Alpha Transcript
• Negative Sentiment: Large one‑time goodwill impairment drove a GAAP loss — BHC recorded a $1.426B goodwill impairment that produced a GAAP net loss of ~$1.43B (GAAP loss per share $(3.82)), which clouds headline profitability and could concern GAAP-focused investors. PR Newswire Release
• Negative Sentiment: Mixed coverage on estimates — Some outlets flagged an earnings “miss” vs certain consensus figures while others noted an adjusted EPS beat; the mixed read on consensus comparisons may drive near‑term volatility as analysts reconcile adjusted vs GAAP metrics. Zacks Coverage Yahoo: Lags Estimates

Analysts Set New Price Targets

Several research analysts have recently commented on BHC shares. Wall Street Zen downgraded Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a report on Sunday, February 15th. Royal Bank Of Canada decreased their price objective on Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating on the stock in a report on Monday. Weiss Ratings downgraded Bausch Health Cos from a “hold (c)” rating to a “sell (d+)” rating in a report on Thursday, February 19th. Raymond James Financial reiterated a “market perform” rating on shares of Bausch Health Cos in a report on Monday, January 26th. Finally, Barclays reduced their price target on Bausch Health Cos from $8.00 to $7.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 25th. Four investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Reduce” and an average price target of $8.00.

Bausch Health Cos Stock Performance

The company has a market cap of $2.31 billion, a PE ratio of 14.69 and a beta of 0.40. The company has a current ratio of 1.47, a quick ratio of 1.08 and a debt-to-equity ratio of 54.68. The business has a fifty day moving average of $5.50 and a 200-day moving average of $6.19.

Bausch Health Cos (NYSE:BHC) last released its quarterly earnings results on Wednesday, February 18th. The company reported $1.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.21 by ($0.13). Bausch Health Cos had a return on equity of 875.00% and a net margin of 1.53%.The company had revenue of $2.78 billion during the quarter, compared to the consensus estimate of $2.71 billion. Equities research analysts anticipate that Bausch Health Cos Inc. will post 4.15 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Paulson & CO. Inc. grew its holdings in shares of Bausch Health Cos by 3.5% during the 4th quarter. Paulson & CO. Inc. now owns 73,255,869 shares of the company’s stock worth $509,128,000 after acquiring an additional 2,500,000 shares during the period. Goldentree Asset Management LP grew its holdings in shares of Bausch Health Cos by 1.7% during the 3rd quarter. Goldentree Asset Management LP now owns 34,833,431 shares of the company’s stock worth $224,409,000 after acquiring an additional 578,542 shares during the period. Vanguard Group Inc. grew its holdings in shares of Bausch Health Cos by 4.0% during the 3rd quarter. Vanguard Group Inc. now owns 12,241,072 shares of the company’s stock worth $78,808,000 after acquiring an additional 470,968 shares during the period. Goldman Sachs Group Inc. grew its holdings in shares of Bausch Health Cos by 65.7% during the 4th quarter. Goldman Sachs Group Inc. now owns 5,143,641 shares of the company’s stock worth $35,748,000 after acquiring an additional 2,038,813 shares during the period. Finally, Norges Bank purchased a new position in shares of Bausch Health Cos during the 4th quarter worth approximately $25,592,000. Hedge funds and other institutional investors own 78.65% of the company’s stock.

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.